Antiangiogenic therapies have shown varying results partly because each tumor type secretes a distinct panel of angiogenic factors to sustain its own microvascular network. In addition, recent evidence demonstrated that tumors develop resistance to antiangiogenic therapy by turning on alternate angiogenic pathways when one pathway is therapeutically inhibited. Here, we test the hypothesis that expression of a caspase-based artificial death switch in tumor-associated endothelial cells will disrupt tumor blood vessels and slow down tumor progression irrespective of tumor type. Adenoviral vectors expressing inducible Caspase-9 (iCaspase-9) under transcriptional regulation with the endothelial cell-specific vascular endothelial growth factor receptor-2 (VEGFR2) promoter (Ad-hVEGFR2-iCaspase-9) induced apoptosis of proliferating human dermal microvascular endothelial cells (HDMECs), but not human tumor cells (UM-SCC-17B, head and neck squamous cell carcinoma; HepG2, hepatocellular carcinoma; PC-3, prostate adenocarcinoma; SLK, Kaposi's sarcoma; MCF-7, breast adenocarcinoma). Notably, apoptosis was dependent upon activation of iCaspase-9 with the dimerizer drug AP20187. Local delivery of Ad-hVEGFR2-iCaspase-9 followed by intraperitoneal injection of AP20187 ablated tumor microvessels and inhibited xenografted tumor growth in all tumor models evaluated here. We conclude that a cancer gene therapy strategy based on a transcriptionally targeted viral vector expressing an inducible caspase allows for selective and controlled ablation of microvessels of histopathologically diverse tumor types.
Introduction
An important, and perhaps unexpected finding of clinical trials with antiangiogenic drugs for cancer treatment is that patients are showing signs of resistance to therapy. 1 Acquired drug resistance may be due to the fact that tumor cells secrete several angiogenic factors that have prosurvival effects for endothelial cells. 2 The engagement of alternate prosurvival pathways for endothelial cells may cancel the proapoptotic effect of the antiangiogenic agent. The direct activation of potent inducers of apoptosis (for example, Caspase-9) in endothelial cells might be a way to circumvent resistance to antiangiogenic therapies, as these agents may not be sensitive to the panel of endothelial cell survival factors secreted by tumor cells. Indeed, we have demonstrated that potent inducers of endothelial cell survival, such as vascular endothelial growth factor (VEGF) or Basic fibroblast growth factor, cannot protect endothelial cells from apoptosis induced by activated Caspase-9. 3 Therefore, specific delivery and controlled activation of the Caspase-9 in tumor-associated endothelial cells might be beneficial for patients with cancer.
Caspases are cysteine proteases that are expressed in mammalian cells as proenzymes that require activation to induce apoptosis. 4 Oligomerization of Caspase-9 mediated by Apaf-1 results in Caspase-9 autocatalysis, irreversible activation of downstream effector caspases such as Caspase-3 and apoptosis of the cell. 5 Artificial death switches based on chemically induced dimerization of caspases with lipid-permeable, nontoxic, dimerizer drugs have been described. 6, 7 When the catalytic domain of Caspase-9 is fused to one or more Fv domains (chemically induced dimerization-binding domain), the resulting fusion protein named inducible Caspase-9 (iCaspase-9) can be activated with a dimerizer drug (AP20187) and initiates signaling that results in cell death. We have shown that activation of iCaspase-9 mediates processing of endogenous Caspase-3 and apoptosis of endothelial cells in vitro. 3 Furthermore, activation of iCaspase-9, in the absence of any other signal, was sufficient to induce endothelial cell apoptosis and to disrupt functional microvessels in vivo. 3 However, a limitation of an antiangiogenic strategy based on the activation of Caspase-9 to disrupt microvessels is the fact that Caspase-9 is ubiquitously expressed in mammals. Therefore, such a strategy requires targeted expression of Caspase-9 to the endothelial cells of newly formed blood vessels in tumors.
The neovascular endothelial cells of tumors express unique genes that differentiate them from endothelial cells lining quiescent blood vessels, and also differentiate them from other cell types. 8, 9 An example of a gene that is preferentially expressed in tumor-associated blood vessels is the VEGF receptor-2 (VEGFR2). 10, 11 A 939-bp VEGFR2 promoter fragment and a 430-bp mouse VEGFR2 enhancer fragment were shown to drive expression of therapeutic genes to the endothelium of tumors for antiangiogenic tumor therapy. 10 The VEGFR2 promoter and enhancer mediated strong, endothelium-specific reporter gene expression in mammary adenocarcinomas grown in transgenic mice, while reporter gene expression was absent from most blood vessels in normal tissues.
A retrovirally delivered 494 bp fragment (À226 to þ 268) of the human VEGFR2 promoter was shown to mediate expression primarily in endothelial cells. 12, 13 Indeed, we have observed that the human VEGFR2 promoter drives approximately 50-fold higher expression of a luciferase reporter construct in human endothelial cells than in human fibroblasts. 14 In addition, we have demonstrated that activation of iCaspase-9 delivered with the targeted adenoviral vector was capable of disrupting microvascular networks engineered in immunodeficient mice.
14 However, the ability of iCaspase-9 to disrupt tumor blood vessels when delivered with a transcriptionally targeted viral vector, and the antitumor effect of such gene-based therapeutic strategy are not known. Here, we demonstrate that activation of a caspase-based artificial death switch delivered with a transcriptionally targeted adenoviral vector to neovascular endothelial cells is sufficient to decrease tumor microvessel density and slowdown progression of a panel of histopathologically distinct cancer types (that is, adenocarcinoma, squamous cell carcinoma, hepatocellular carcinoma and sarcoma).
Materials and methods

Flow cytometry
Human dermal microvascular endothelial cells (HDMECs, Clonetics, Walkersville, MD, USA), human squamous cell carcinoma cell line UM-SCC-17B (gift from T Carey, University of Michigan), human hepatocellular carcinoma cell line HepG2 (ATCC, Manassas, VA, USA), human prostate adenocarcinoma cell line PC-3 (ATCC), human Kaposi's sarcoma cell line SLK, and human breast adenocarcinoma cell line MCF-7 (ATCC) were infected with adenoviruses expressing iCaspase-9 under transcriptional regulation of the VEGFR2 promoter (that is, Ad-hVEGFR2-iCaspase-9), or no-promoter control adenoviruses (Ad-iCaspase-9), at a 0-200 multiplicity of infection (MOI), as described.
14 After 24 h, cells were exposed to 0-100 nM AP20187 (Ariad Pharmaceuticals, Cambridge, MA, USA) for additional 0-96 h. For evaluation of apoptosis, cells were harvested, washed, stained with 40 mg ml À1 Annexin V (BD Biosciences Clontech, Palo Alto, CA, USA), and evaluated by flow cytometry.
14 For determination of infection efficiency, cells were infected with 0-200 MOI. Ad-iCaspase-9 or Ad-hVEGFR2-iCaspase-9, but were not exposed to AP20187 (Ariad). After 24 h, cells were fixed in 2% paraformaldehyde (Sigma-Aldrich Corp., St Louis, MO, USA), permeabilized with 3% saponin (Sigma-Aldrich), incubated in 1:100 dilution antiHA antibody (Babco, Berkeley, CA, USA) or isotype-matched nonspecific IgG (Santa Cruz, Santa Cruz, CA, USA), for 1 h at 37 1C, and evaluated by flow cytometry.
14 Data were obtained from triplicate wells per cell and condition, and reproducibility of results was verified in three independent experiments. 
Real-time PCR
The HDMEC, UM-SCC-17B, HepG2, PC-3, SLK or MCF-7 cells were seeded in six-well plates and were infected with Ad-iCaspase-9 or Ad-hVEGFR2-iCaspase-9 at 0-200 MOI. After 24 h, total RNA was extracted and treated with DNase I using the RNeasy kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. For reverse transcription, a 50 ml reverse transcription reaction with 1 mg total RNA and random hexamers was performed using TaqMan Reverse Transcription Reagent (Applied Biosystems, Foster City, CA, USA). The thermal settings were as follows: 25 1C for 10 min, 37 1C for 60 min and 95 1C for 5 min. PCR was performed by using TaqMan Universal PCR Master Mix (Applied Biosystems). Briefly, a 30 ml PCR reaction was prepared with 1 ml cDNA (reverse transcription product) and 1.5 ml mixture of gene-specific probe (FAM dye) and primers mixture from Applied Biosystems Custom TaqMan Gene Expression Assays product. For evaluation of expression of iCaspase-9, the following primers and probe were used: forward primer: TGGTTGCTTTA ATTTCCTCCGGAA; reverse primer: GCTTTTTGCT TTGTGTTGTTTTGCT; probe: TCATAAACATGATG AACCCC. The thermal settings were as follows: 50 1C for 2 min, 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s, and 60 1C for 1 min, in an ABI Prism Sequence Detection System 7700 (Applied Biosystems).
SCID mouse model of human tumor angiogenesis
Xenografted tumors vascularized with functional human microvessels were induced in severe combined immunodeficient (SCID) mice (CB-17 SCID; Taconic, Germantown, NY, USA), as described. [14] [15] [16] Briefly, 0.9 Â 10 6
HDMECs were mixed with 0.1 Â 10 6 UM-SCC-17B, HepG2, SLK or PC-3 cells and seeded in poly-(L-lactic acid) (PLLA, Medisorb, Cincinnati, OH, USA) biodegradable scaffolds. Two scaffolds were implanted subcutaneously into the dorsum of each SCID mouse (CB-17 SCID), in 12 mice per tumor cell line. After 10 days of implantation, 12 tumors were locally injected with 5 Â 10 10 Ad-iCaspase-9 virus particles, while additional 12 tumors were locally injected with 5 Â 10 10 AdhVEGFR2-iCaspase-9 virus particles. After viral administration, animals received daily intraperitoneal injections of either 2 mg kg À1 AP20187 (Ariad) in a solution of 10% PEG 400 and 1.7% Tween 20 or equivalent volume of control phosphate-buffered saline (PBS) for 3 consecutive days. The volumes of the tumors were measured every 3 days for 21 days, when mice were euthanized. Immediately after euthanasia, tumors were retrieved, weighed, measured and fixed in 10% neutral buffered formalin for 30 min at 4 1C, before processing for histology.
Immunolocalization of tumor microvessels Microvessels were identified by incubating tissue sections with polyclonal rabbit antihuman Factor VIII antibody (Lab Vision Corp., Freemont, CA, USA). 15 The number of stained microvessels was counted in five randomly selected fields per implant at Â 200, from 12 implants per condition.
Statistical analysis
Statistical significance was determined at the Po0.05 level, using one-way ANOVA and the Student-NewmanKeuls test (SigmaStat 2.0, SPSS, Chicago, IL, USA).
Results
Transcriptional targeting with VEGFR2 promoter drives expression specifically in proliferating endothelial cells, not tumor cells To evaluate the specificity of gene expression mediated by the VEGFR2 transcriptionally targeted adenoviruses, we screened primary human endothelial cells and a diverse panel of tumor cell lines for reporter gene (that is, LacZ) expression using b-galactosidase staining in vitro. The selection of the tumor cell lines used here reflected our attempt to test the specificity of our endothelial-targeted adenoviral vector, and at the same time, to test the robustness of the antiangiogenic strategy for treatment of a diverse group of tumor types. We elected to use cell lines derived from two adenocarcinomas, one squamous cell carcinoma, one hepatocellular carcinoma and one sarcoma, from diverse sites such as breast, prostate and liver. Infection of endothelial cells with Ad-hVEGFR2-LacZ mediated strong reporter gene expression, while none of the tumor cells expressed the reporter gene at levels beyond the cells infected with no promoter controls (Figures 1a and b) . To confirm that lack of reporter gene expression was not simply due to differential infection efficiency, we used the nonspecific cytomegalovirus (CMV) promoter. Infection with Ad-CMV-LacZ mediated strong reporter gene expression in all cell lines screened here (Figures 1a and b) . Notably, in primary endothelial cells the VEGFR2 promoter drives expression of the reporter gene at levels similar to those observed with the CMV promoter, while maintaining specificity to the endothelium (Figures 1a and b) .
Transcriptional targeting of iCaspase-9 with the VEGFR2 promoter allows for expression and dimerizer drug-induced apoptosis of endothelial cells, but not tumor cells As the overall aim of this study is to evaluate the effect of an adenovirus-based antiangiogenic gene therapy on tumor growth, it is critical to evaluate whether the viruses used here drive expression of our therapeutic gene (that is, iCaspase-9) specifically in endothelial cells. To address this question, we substituted the LacZ cassette by the iCaspase-9 cassette in the VEGFR2-targeted adenoviral vector, infected endothelial cells and a panel of tumor cell lines and performed flow cytometry for the hemagglutinin (HA) tag (iCaspase-9 is HA-tagged). We observed that nearly 100% of the endothelial cells infected with AdhVEGFR2-iCaspase-9 were HA positive, while none of the tumor cells expressed iCaspase-9 at levels beyond background (Figure 2a) . To further test transcriptional activity of the construct, we performed real-time PCR for iCaspase-9. To ensure that we were measuring expression of the transduced gene, not endogenous Caspase-9, we designed the forward primer within the Caspase-9 sequence and the reverse primer within the HA sequence. In support to our previous findings, infection with AdhVEGFR2-iCaspase-9 drove strong expression of the therapeutic gene in endothelial cells, but not in any of the tumor cells evaluated (Figure 2b) . Notably, our nopromoter adenoviruses proved to be an acceptable control for our in vivo studies, as they do not mediate expression activity beyond background both at the RNA and at the protein levels (Figures 2a and b) .
Once specificity of iCaspase-9 expression in endothelial cells was determined, we performed studies to verify the level of cell death control that was mediated by the inducible caspase system. Here, we infected primary endothelial cells or the tumor cell lines with AdhVEGFR2-iCaspase-9 or control adenoviruses, exposed them to the dimerizer drug AP20187, which will activate the caspase-based artificial death switch iCaspase-9, and performed Annexin V staining for apoptotic cells followed by flow cytometry. We observed significant induction of apoptosis in the endothelial cells treated with AP20187, but not in the tumor cells (Figure 3) . Notably, the iCaspase-9 system allowed for exquisite control of induction of death, as vehicle-treated endothelial cells did not undergo apoptosis (Figure 3 ). In addition, AP20187 was not toxic to endothelial cells transduced with nopromoter control adenoviruses or tumor cells (Figure 3 ). Caspase-3 is a known downstream effector of Caspase-9-mediated apoptotic activity. 4 To demonstrate that the cell death induced by AP20187 is not just nonspecific cytotoxicity, we performed fluorimetric assays for Caspase-3 activity in the endothelial cells and in the tumor cell lines used here. We observed a significant increase in Caspase-3 activity only in the endothelial cells exposed to AdhVEGFR2-iCaspase-9 and treated with AP20187, but not in any of the controls or in tumor cells (data not shown). These experiments confirmed that activation of adenovirally transduced iCaspase-9 with AP20187 was sufficient to engage the endogenous Caspase-3 pathway, ultimately resulting in endothelial cell apoptosis.
iCaspase-9 delivered with an adenoviral vector transcriptionally targeted to the tumor vasculature inhibits tumor growth and decreases tumor microvascular density upon activation of the artificial death switch To evaluate the effect of the activation of the caspase-based artificial death switch delivered by the Ad-hVEGFR2-iCaspase-9 vector on tumor growth and vascularization, we utilized the SCID mouse model of human tumor angiogenesis that was developed and characterized by our group. 15, 16 This model allows for the generation of human tumors vascularized with human blood vessels in immunodeficient murine hosts by using a tissue engineering-based approach. Here, we present the results of experiments with three representative tumor xenografts, that is, the HepG2, UM-SCC-17B and SLK tumors, vascularized with human endothelial cells (HDMECs) (Figure 4 ). All tumors were retrieved 21 days after transplantation. As each tumor type grows at a different pace after subcutaneous transplantation, we observed that the control tumors (that is, PBS-treated tumors that were injected with no-promoter Ad-iCaspase-9 adenoviruses) had grown to different sizes after this period of time. Notably, the SLK-based tumors were larger than the other two groups (Figure 4) . In spite of the difference in control tumor size, all three different tumor types presented similar trends of response to the gene therapy approach utilized here. We observed that tumors injected with Ad-hVEGFR2-iCaspase-9 viruses in mice that received intraperitoneal injections of the dimerizer drug AP20187 were consistently smaller (Po0.05) than PBS-treated mice or tumors that were injected with the no-promoter control Ad-iCaspase-9 adenoviruses (Figure 4 ). AP20187-treated UM-SCC-17B tumors injected with control Ad-iCaspase-9 adenoviruses showed some decrease in size as compared to tumors injected with the same adenoviruses in mice treated with PBS (Figure 4 ), but the size difference was not statistically significant (P40.05). The reduction in tumor growth mediated by the antiangiogenic gene therapy proposed here was tightly regulated, that is, only AP20187-treated mice experienced it. Notably, the mean volume of tumors injected with AdhVEGFR2-iCaspase-9 in mice treated with AP20187 was 13-37% of the mean volume of control tumors injected with no-promoter Ad-iCaspase-9 and treated with PBS ( Figure 4) . To confirm the antiangiogenic activity of adenovirally delivered iCaspase-9 transcriptionally targeted to endothelial cells, and to understand the mechanisms underlying its antitumor effects, we analyzed tumor microvessel density by staining tumor microvessels with antiFactor VIII antibody. 15 In the three tumor types evaluated, we observed a decrease in microvessel density in tumors injected with Ad-hVEGFR2-iCaspase-9 in mice treated with AP20187, as compared to controls (Po0.05) ( Figure 5 ). Here again, the number of blood vessels per microscopic field varied according to tumor type, but the trend among the three tumor types evaluated here was similar. Furthermore, the effect on the microvasculature was observed only when mice were treated with AP20187, which confirms the high level of control conferred by this inducible system of cell death ( Figure 5 ). In addition, TUNEL staining demonstrated increased apoptosis in tumors injected with Ad-hVEGFR2-iCaspase-9 in mice treated with AP20187 as compared to controls (data not shown). Figure 6 depicts representative microscopic fields of xenografted HepG2 tumors stained with antiFactor VIII antibody, where a notable decrease in vascular density is observed in AP20187-treated mice bearing tumors that were injected with Ad-hVEGFR2-iCaspase-9. 
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Thus, local injection of transcriptionally targeted iCaspase-9 induces apoptosis of endothelial cells and disruption of tumor microvessels in vivo upon conditional induction of Caspase-9 activity with a dimerizer drug. Taken together, these results demonstrate that the antiangiogenic gene therapy approach for cancer presented here is robust (that is, reduces progression of histologically diverse tumor types) and controllable (that is, the antitumor effect is dependent upon administration of the dimerizer drug AP20187).
Discussion
A gene therapy approach for cancer treatment based on the delivery of an apoptotic gene to tumor cells is effective if all tumor cells are eliminated. 17 In contrast, a therapeutic strategy that is targeted to the neovascular compartment of the tumor might be beneficial for the patient even if it does not lead to the transduction of the therapeutic gene into every tumor-associated endothelial cell. This is due to the fact that it is not necessary to kill progression is inhibited by intratumoral injection of the adenovirus Ad-VEGFR2-iCaspase-9 and administration of AP20187. Graphs depicting tumor volume (±s.d.) of mice bearing tumors (HepG2, UM-SCC-17B or SLK) injected with either Ad-VEGFR2-iCaspase-9 or Ad-iCaspase-9 (no promoter control), and treated with either 2 mg kg À1 AP20187 or phosphate-buffered saline (PBS). Statistical significance (*) was determined at Po0.05, using the volume obtained for the Ad-iCaspase-9 þ PBS group as control. Data represent mean values ( ± s.d.) of 12 tumors per experimental condition.
Caspase-mediated antiangiogenic gene therapy W Song et al each endothelial cell to disrupt a microvessel. Indeed, we have recently demonstrated that a significant decrease in tissue microvascular density is observed when 22% or more endothelial cells lining the walls of blood vessels are apoptotic. 18 The finding that apoptosis of a relatively small proportion of endothelial cells is sufficient to disrupt blood vessels, coupled with the observation that each blood vessel supports many tumor cells, 19 provide support for gene therapy approaches that target the vascular compartment of tumors.
The translation of gene therapies to the clinic depends on the ability to regulate the expression of the transgene. 20 Figure 5 Tumor angiogenesis is inhibited by intratumoral injection of Ad-VEGFR2-iCaspase-9 and administration of AP20187. Graphs depicting microvessel density (±s.d.) of xenografted tumors (HepG2, UM-SCC-17B or SLK) injected with either Ad-VEGFR2-iCaspase-9 or promoterless Ad-iCaspase-9 control, and treated with either 2 mg kg À1 AP20187 or phosphate-buffered saline (PBS). Statistical significance is depicted by lowercase letters, as follows: (a) microvessel density is not significantly different (P40.05) when tumors that received injection of Ad-VEGFR2-iCaspase-9 in mice treated with PBS are compared with tumors that received injection of promoterless Ad-iCaspase-9 in mice treated with either AP20187 or PBS; and (b) microvessel density is significantly lower (*Po0.05) in tumors that received injection of Ad-VEGFR2-iCaspase-9 in mice treated with AP20187 as compared to the three other experimental conditions. Data represent mean values ( ± s.d.) of 12 tumors per experimental condition. Figure 6 Effect of activation of adenovirally delivered iCaspase-9 on tumor microvessels. (a-d) Photomicrographs of representative histological sections after immunochemistry with Factor VIII antibody to identify tumor blood vessels. Xenografted tumors (HepG2) were retrieved from mice that received local injection of either Ad-VEGFR2-iCaspase-9 or promoterless Ad-iCaspase-9 control viruses, and were treated with either phosphate-buffered saline (PBS) or 2 mg kg À1 AP20187.
Caspase-mediated antiangiogenic gene therapy W Song et al
Ideally, this regulation should be achieved with the use of a cell permeable drug that is nontoxic to nontransduced cells, does not elicit adverse immune responses and that has an adequate half-life to allow for the regulation of transgene expression accordingly. 20 These features allow for the discontinuation of transgene expression if adverse effects are observed in the patient or if gene therapy is no longer needed. In this study, we utilized a caspase-based artificial death switch that has these characteristics. We did not observe signs of toxicity of the dimerizer drug in animals, as demonstrated by the absence of significant loss of weight in AP20187-treated mice. Furthermore, the drug was delivered intraperitonealy but its effect was observed only in the subcutaneous tumors. As mice did not show signs of hemorrhage in other organs or tissues, we conclude that local delivery of Ad-hVEGFR2-iCaspase-9 followed by systemic administration of the dimerizer drug led to an antiangiogenic effect limited to the tumor vasculature. Notably, delivery of promoterless control adenoviruses followed by intraperitoneal AP20187 resulted in the absence of local and systemic observable effects. Taken together, these observations demonstrate that a cancer gene therapy strategy based on a transcriptionally targeted viral vector expressing a caspase-based artificial death switch allows for selective and controlled ablation of tumor microvessels.
Specific expression of therapeutic genes in a targeted cell population, and therefore enhanced safety of the gene therapy approach, can be achieved by transcriptionally targeting the viral vectors. [21] [22] [23] Here, we showed expression of reporter constructs and iCaspase-9 in normal, proliferating, endothelial cells using the VEGFR2 transcriptionally targeted adenoviral vector in vitro. However, we did not observe disruption of physiologic blood vessels (as determined by the absence of signs of hemorrhage) or cytotoxicity (as determined by the absence of significant mouse weight loss) in the animals that received Ad-VEGFR2-iCaspase-9 and that were treated with AP20187. We reasoned that these apparently conflicting results could be explained by the fact that the transcriptional activity of VEGFR2 is higher in proliferating endothelial cells than in quiescent cells. This hypothesis is based on the observation that VEGFR2 is downregulated in most adult (quiescent) vascular networks, while it is upregulated in the blood vessels of several human tumors, including carcinomas and gliomas. 24, 25 Indeed, expression of reporter constructs driven by the VEGFR2 promoter has been reported to be specific to tumor endothelium, and absent from the physiologic vasculature proposed by Heidenreich et al. 10 Therefore, under transcriptional regulation of the VEGFR2 promoter, iCaspase-9 will not be transcribed as efficiently in the more mature and quiescent endothelial cells from host blood vessels. Together, these studies offer an explanation for our observation that host blood vessels are spared while the tumor-associated blood vessels are disrupted upon local injection of Ad-VEGFR2-iCaspase-9 and administration of the dimerizer drug.
Transcriptional targeting of viral vectors to the tumor vasculature has been successfully done earlier in many laboratories. 26 A novelty of the current study is that we used a targeted viral vector to deliver an inducible therapeutic 'cargo' that only triggers apoptosis to recipient endothelial cells upon its activation with a dimerizer drug. The combination of the caspase-based artificial death switch with a neovascular endothelialtargeted vector makes this vector rather unique and provides an extra layer of safety to the cancer gene therapy approach. In addition to the demonstrated specificity of expression of iCaspase-9 in endothelial cells and not in other stromal cells such as fibroblasts, 14 the cytotoxic 'cargo' is only functional when activated with the nontoxic dimerizer drug. This was demonstrated in experiments were we did not observe an antiangiogenic or antitumor effect of the Ad-hVEGFR2-iCaspase-9 vector in mice that were not injected with the dimerizer drug AP20187. A feature that provides additional safety to this approach is the fact that cells that are transduced with the adenoviruses tested here will undergo apoptosis upon exposure to the dimerizer drug. Therefore, risks associated with viral-induced cell transformation are minimized by the fact that transduced cells will undergo apoptosis and be eliminated.
Here, we report the antiangiogenic and antitumor effects observed 11 days after a single injection of the adenoviral vector. However, we do not know what is the upper limit of time that one can still observe a significant reduction in tumor volume and microvessel density with this therapeutic strategy. Considering the transient expression of therapeutic genes typically observed with adenoviral vectors, we speculate that the treatment of large or highly angiogenic tumors may require more than one cycle of adenoviral administration followed by activation of iCaspase-9 with the dimerizer drug.
One of the fundamental premises tested in this study was that an adenoviral vector transcriptionally targeted to the vasculature would allow for a therapeutic benefit in diverse tumor types. In proof-of-principle experiments, we selected histopathologically distinct tumor types (for example, adenocarcinoma, squamous cell carcinoma, sarcoma) from diverse organ sites (that is, prostate, breast, head and neck, liver) to test our viral vector. Notably, we observed that all tumor types tested here responded to therapy by a significant reduction of tumor growth that was correlated with significant decrease in microvascular density. Such tumors likely produce diverse angiogenic factors that signal survival to endothelial cells through distinct pathways. However, the direct activation of a downstream effector of apoptosis (that is, Caspase-9) overrides upstream prosurvival signals for endothelial cells, inducing cell death and consequent decrease in microvascular density in all tumors evaluated here.
In summary, we present here data that demonstrate that an adenoviral vector transcriptionally targeted to endothelial cells by the use of the VEGFR2 promoter drives specific expression of reporter genes and iCaspase-9 in neovascular endothelial cells. In addition, we show that the transcriptionally targeted adenoviruses have a significant antitumor effect and induce a potent inhibition of tumor angiogenesis. Notably, these effects are exquisitely regulated by the administration of a dimerizer drug that is nontoxic to cells that do not express the inducible caspase. We believe that transcriptionally targeted viral vectors expressing inducible caspases may constitute a powerful new approach for antiangiogenic gene therapy for cancer.
